Equities

ReNeuron Group PLC

ReNeuron Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)27.50
  • Today's Change-1.00 / -3.51%
  • Shares traded70.16k
  • 1 Year change-74.65%
  • Beta1.9297
Data delayed at least 20 minutes, as of Jun 27 2022 16:14 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company’s stem cell derived Exosome Technology platform offers a delivery mechanism for a variety of payloads, such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. The Company has two clinical-stage stem cell therapy candidate assets, a Phase 2a human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa and a Phase 2b immortalized neural progenitor cell therapy candidate (CTX) in stroke. The Company through its induced pluripotent stem cell (iPSC) platform has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)274.00k
  • Net income in GBP-9.49m
  • Incorporated2005
  • Employees43.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttp://www.reneuron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Parity Group plc4.08m-636.00k8.63m35.00--1.23--2.12-0.0062-0.00620.03970.06820.2888--0.7535116,571.40-4.500.4326-9.171.11-----15.590.2286---3.840.26630.00-26.63-46.35-35.32---10.86--
Aquila Services Group PLC8.99m260.00k10.39m76.0041.141.7727.341.160.00630.00630.22090.14691.15--4.10118,263.203.335.384.297.2822.6623.642.894.52----0.052674.00-4.0310.0048.41---15.59-3.58
ValiRx Plc0.00-1.52m10.90m7.00--3.03-----0.0234-0.02340.000.05530.00----0.00-36.57-58.96-35.94-77.90-----------605.720.0169-------5.19------
React Group PLC7.70m389.00k11.28m28.0015.811.9617.281.470.00070.00070.01360.00551.64--4.83--8.29-13.5213.61-19.1730.7629.505.05-9.141.00--0.0356--76.6325.93106.91---19.50--
Bivictrix Therapeutics PLC0.00-2.34m13.22m5.00--2.09-----0.1694-0.16940.000.09570.00----0.00-58.88---64.64-------------2.340.0374-------450.59------
Afriag Global PLC0.00-2.16m13.47m18.00--0.8236-----0.0665-0.06650.000.02190.00-------82.61-21.17-126.34-30.96--7.04---25.49---7.120.00---100.00---586.16------
All Things Considered Group PLC11.13m-1.95m14.57m17.00------1.31-0.2038-0.20381.16-0.24422.49--5.84654,821.80-64.96---512.72---1.80---26.07-----10.01----127.06--31.23------
Silver Bullet Data Services Group Ltd3.81m-8.51m15.03m62.00--1.38--3.94-0.6342-0.63420.28390.6878----------------73.11---223.42-----406.120.017--36.58---66.28------
One Media IP Group PLC4.39m544.58k15.24m11.0030.181.0312.763.470.00230.00230.01640.06640.2548--3.35399,052.703.164.403.364.7774.9155.5312.4113.60--4.590.1058--9.5916.50-13.5954.0079.06-4.98
NAHL Group PLC38.95m156.00k16.12m259.00103.260.28473.050.41390.00340.00340.84221.220.3915--1.59150,374.503.635.674.627.0845.1848.169.2611.87--8.840.26293.43-4.72-4.64169.33-58.20-0.1605--
ReNeuron Group Plc274.00k-9.49m16.26m43.00--1.15--59.35-0.1854-0.18540.00540.24860.0149--0.40536,372.09-51.51-34.68-86.63-40.80-----3,463.14-1,088.16---68.980.0429---95.7654.710.5696---38.88--
ImmuPharma PLC118.35k-8.17m17.78m14.00--4.03--150.26-0.0325-0.03250.00050.01550.014--0.40178,453.57-96.66-94.13-116.20-109.64-----6,906.55-6,235.41---2.190.0002---6.57-6.40-19.15--60.85--
Gattaca PLC411.39m-701.00k19.54m540.00--0.62318.630.0475-0.0219-0.078212.710.9714.61--8.09851,741.20-0.7856-2.23-1.81-4.2810.3510.76-0.1704-0.5376--3.200.3055---22.25-7.61146.08-29.0018.76-42.07
National Milk Records Plc22.58m2.36m21.13m276.008.952.956.530.9360.11120.11121.060.33751.7822.886.1381,804.3518.65--27.74--42.79--10.46--1.41--0.2209--1.51--102.78------
Skillcast Group PLC8.41m377.63k21.47m86.0052.062.9732.512.550.00460.00460.10360.0807------97,768.14--------70.54--4.49-----35.610.0818--15.29---58.23------
Deepverge PLC6.80m-4.23m22.52m9.00--0.8716--3.31-0.0256-0.02560.04140.11760.33713.774.12---20.99-43.87-24.27-66.6643.7045.96-62.27-222.572.36-8.070.1056--444.71306.88-19.68--10.16--
Data as of Jun 27 2022. Currency figures normalised to ReNeuron Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

38.90%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 May 20224.32m7.57%
Jarvis Investment Management Ltd.as of 02 May 20223.62m6.34%
Octopus Investments Ltd.as of 04 Jun 20213.35m5.87%
Schroder Investment Management Ltd.as of 12 Mar 20212.84m4.97%
Woodford Investment Management Ltd.as of 02 May 20222.43m4.25%
Hargreaves Lansdown Asset Management Ltd.as of 02 May 20222.41m4.23%
Walker Crips Investment Management Ltd.as of 02 May 20221.18m2.07%
KW Investment Management Ltd.as of 02 May 2022755.00k1.32%
IG Markets Ltd.as of 02 May 2022671.00k1.18%
Smith & Williamson Investment Management LLPas of 02 May 2022630.00k1.10%
More ▼
Data from 31 Mar 2022 - 02 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.